Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (20)

2012

  1. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer

    Cancer Chemotherapy and Pharmacology, Vol. 70, Núm. 6, pp. 883-890

  2. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

  3. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum

    Lung Cancer, Vol. 76, Núm. 3, pp. 354-361

2011

  1. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine

    Lung Cancer, Vol. 71, Núm. 2, pp. 191-198

2009

  1. Predictors of long-term survival in patients with lung cancer included in the Randomized Spanish Lung Cancer Group 0008 Phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy

    Clinical Lung Cancer, Vol. 10, Núm. 3, pp. 180-186

2007

  1. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 25, Núm. 19, pp. 2747-2754

2006

  1. Methylation patterns and chemosensitivity in NSCLC.

    Advances in experimental medicine and biology, Vol. 587, pp. 195-209

  2. The place of targeted therapies in the management of non-small cell bronchial carcinoma: Molecular markers as predictors of tumor response and survival in lung cancer

    Revue des Maladies Respiratoires, Vol. 23, Núm. 5 C3

2005

  1. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer

    Annals of Oncology, Vol. 16, Núm. 4, pp. 597-601

2004

  1. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer

    Clinical Lung Cancer, Vol. 5, Núm. 6, pp. 360-365

  2. Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

    Clinical Cancer Research, Vol. 10, Núm. 4, pp. 1318-1325

  3. The promise of pharmacogenomics: gemcitabine and pemetrexed.

    Oncology (Williston Park, N.Y.), Vol. 18, Núm. 13 Suppl 8, pp. 70-76

2003

  1. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial

    Journal of Clinical Oncology, Vol. 21, Núm. 17, pp. 3207-3213

  2. Genetic testing for chemotherapy in non-small cell lung cancer

    Lung Cancer

  3. Targeted therapy in combination with gemcitabine in non-small cell lung cancer

    Seminars in Oncology

2002

  1. Determinants of response and resistance to cytotoxics

    Seminars in Oncology, Vol. 29, Núm. 1 SUPPL. 4, pp. 110-118

  2. Low ERRC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer

    Clinical Cancer Research, Vol. 8, Núm. 7, pp. 2286-2291

2001

  1. Novel approaches in the treatment of non-small-cell lung cancer

    ONCOLOGY, Vol. 15, Núm. 3 SUPPL. 6, pp. 52-60

  2. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 19, Núm. 4, pp. 1071-1077

1995

  1. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: Links between p53 and K-ras gene status and chemosensitivity

    Seminars in Oncology, Vol. 22, Núm. 6 SUPPL. 14, pp. 12-18